- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Insights and advances in chronic urticaria: a Canadian...
Open Collections
UBC Faculty Research and Publications
Insights and advances in chronic urticaria: a Canadian perspective Sussman, Gordon; Hébert, Jacques; Gulliver, Wayne; Lynde, Charles; Waserman, Susan; Kanani, Amin; Ben-Shoshan, Moshe; Horemans, Spencer; Barron, Carly; Betschel, Stephen; et al.
Abstract
In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
Item Metadata
Title |
Insights and advances in chronic urticaria: a Canadian perspective
|
Creator | |
Publisher |
BioMed Central
|
Date Issued |
2015-02-11
|
Description |
In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2016-02-04
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0223971
|
URI | |
Affiliation | |
Citation |
Allergy, Asthma & Clinical Immunology. 2015 Feb 11;11(1):7
|
Publisher DOI |
10.1186/s13223-015-0072-2
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty
|
Copyright Holder |
Sussman et al.; licensee BioMed Central.
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)